Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors

Metastatic prostate cancer is initially sensitive to androgen receptor inhibition, but eventually becomes castration-resistant prostate cancer (mCRPC). Early use of more intensive therapies targeting androgen receptor and other oncogenic drivers in treatment-naïve primary prostate cancer (PC) may be...

Descripción completa

Detalles Bibliográficos
Autores principales: Einstein, David J., Arai, Seiji, Calagua, Carla, Xie, Fang, Voznesensky, Olga, Capaldo, Brian J., Luffman, Christina, Hecht, Jonathan L., Balk, Steven P., Sowalsky, Adam G., Russo, Joshua W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457789/
https://www.ncbi.nlm.nih.gov/pubmed/34568716
http://dx.doi.org/10.1200/PO.21.00059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457789/
https://www.ncbi.nlm.nih.gov/pubmed/34568716
http://dx.doi.org/10.1200/PO.21.00059

Ejemplares similares